Reckitt Benckiser Group plc

What does Reckitt own?

Reckitt owns 11 Powerbrands across health, hygiene, and nutrition. Hygiene brands include Dettol, Lysol, Harpic, Vanish, Finish, and Air Wick. Health brands include Mucinex, Nurofen, Strepsils, Gaviscon, and Durex. Nutrition brands include Enfamil and Nutramigen. These brands are sold in over 200 countries and generated £14.2 billion in net revenue in FY2025. The company divested its Essential Home business in December 2025 for £2.172 billion to focus on its core Powerbrands.

Is Reckitt publicly traded?

Yes, Reckitt Benckiser Group plc is listed on the London Stock Exchange under ticker RKT and is a constituent of the FTSE 100 Index. The company has been publicly traded since the merger of Reckitt and Colman and Benckiser NV in 1999. Ownership is broadly distributed among institutional investors including Vanguard Group, BlackRock, and State Street Global Advisors. No single shareholder holds a controlling stake.

Who founded Reckitt?

Reckitt was formed in 1999 through the merger of Reckitt and Colman, founded in 1840 by Isaac Reckitt in Hull, England, and Benckiser NV, founded in 1823 by Johann Benckiser in Pforzheim, Germany. The merger combined two centuries-old household products companies into a single entity. Bart Becht, a Benckiser executive, became the first CEO of the combined company and led it through its formative years of brand acquisition and portfolio building.

Where is Reckitt headquartered?

Reckitt is headquartered in Slough, England, United Kingdom. The company maintains major operations centers in the United States, China, India, and other key markets. Its manufacturing facilities are located across six countries, including the United Kingdom, United States, China, India, Mexico, and Thailand. The company's corporate functions and global leadership team are based in Slough.

How many brands does Reckitt own?

Reckitt owns 11 Powerbrands that generate the majority of its revenue. These are Dettol, Lysol, Harpic, Vanish, Finish, Air Wick, Mucinex, Nurofen, Strepsils, Gaviscon, and Durex, plus the Enfamil and Nutramigen nutrition brands. The company previously owned a broader portfolio but has divested non-core businesses, including its food brands (sold to McCormick in 2017) and its Essential Home business (sold in December 2025 for £2.172 billion).

Who owns Reckitt?

Reckitt Benckiser Group plc is owned by public shareholders, with institutional investors holding the majority of shares. Major institutional shareholders include Vanguard Group, BlackRock, and State Street Global Advisors. There is no controlling shareholder or founding family stake. The board is chaired by Sir Jeremy Darroch, and CEO Kris Licht manages the business. The company returned £2.3 billion to shareholders in FY2025 through buybacks and dividends, plus a special dividend of approximately £1.6 billion in February 2026 from the Essential Home divestment proceeds.

What are Reckitt's largest or most valuable brands?

Dettol and Lysol are Reckitt's largest brands by revenue, driven by their global disinfection franchise. Mucinex is the largest health brand, driven by its US cough and cold market position. Enfamil is the largest nutrition brand, with approximately 35% US infant formula market share. Durex is the world's most widely distributed sexual wellness brand. Finish is the global leader in automatic dishwasher detergent by volume. These five brands collectively account for the majority of Reckitt's revenue.

Has Reckitt made major acquisitions recently?

Reckitt's most recent major acquisition was Mead Johnson Nutrition in February 2017 for $16.6 billion, which brought Enfamil into the portfolio. Since then, the company has focused on divesting non-core assets rather than acquiring new ones. It sold its food brands to McCormick in 2017, spun off Indivior in 2014, and divested its Essential Home business in December 2025 for £2.172 billion. CEO Kris Licht has prioritized organic growth and cost reduction over acquisitions.

The company that became Reckitt Benckiser has roots in two 19th century businesses. Isaac Reckitt founded Reckitt and Sons in Hull, England, in 1840. The company initially produced starch, black lead, and household chemicals. Reckitt and Sons expanded into household cleaning products over the following decades and acquired Colman's, the English mustard company, in 1938 to form Reckitt and Colman. Johann Benckiser founded a chemicals company in Pforzheim, Germany, in 1823. Benckiser NV grew into a major European household cleaning products company under the leadership of the Benckiser family and later Peter Harf.

Reckitt and Colman plc and Benckiser NV merged in December 1999 to create Reckitt Benckiser Group plc. The merger combined Reckitt and Colman's UK and Commonwealth presence with Benckiser's Continental European strength. Bart Becht, a Benckiser executive, became CEO of the combined company. Becht implemented a strategy focused on a small number of core brands, supply chain efficiency, and what he called "innovation marketing," which combined increased marketing spend with continuous product innovation. The approach drove strong revenue growth and margin expansion through the 2000s.

The post-merger years were defined by a series of acquisitions that built Reckitt's health portfolio. In October 2005, Reckitt purchased Boots Healthcare International for £1.9 billion, adding Nurofen, Strepsils, and Clearasil to its portfolio. In January 2008, the company acquired Adams Respiratory Therapeutics for $2.3 billion, bringing the Mucinex brand into the fold. In July 2010, Reckitt acquired SSL International for £2.5 billion, adding Durex condoms and Scholl footcare products.

Rakesh Kapoor succeeded Bart Becht as CEO in September 2011. Kapoor continued the acquisition strategy, purchasing Schiff Nutrition for $1.4 billion in November 2012 to add vitamins and nutritional supplements including Move Free and Airborne. In December 2014, Reckitt spun off its specialty pharmaceuticals business into Indivior, a separately listed company on the London Stock Exchange. The spin-off allowed Reckitt to focus on consumer health and hygiene.

The February 2017 acquisition of Mead Johnson Nutrition for $16.6 billion was the largest deal in Reckitt's history. The purchase brought Enfamil, the second-largest US infant formula brand, into the portfolio. The strategic rationale was to enter the infant nutrition category, which offered attractive demographics and growth prospects. The integration proved challenging. Mead Johnson's growth slowed after the acquisition, and Reckitt took a £5.2 billion impairment charge on the nutrition business in 2019.

Laxman Narasimhan became CEO in September 2019 and initiated a turnaround program. Under Narasimhan, Reckitt sold its infant formula manufacturing facility in Singapore and streamlined operations. In March 2021, the company rebranded from RB to Reckitt, introducing a new logo and visual identity. Narasimhan left Reckitt in September 2022 to become CEO of Starbucks.

Kris Licht, who had joined Reckitt in 2019 as President of the Health business, was appointed CEO Designate in May 2023 and assumed the role of CEO in October 2023. Licht launched a strategy update in summer 2024 that simplified the operating model and focused investment behind the 11 Powerbrands. The company also initiated the Fuel for Growth program, a cost reduction effort targeting fixed costs as a percentage of net revenue.

In 2025, Reckitt completed the divestment of its Essential Home business, which included brands like Air Wick and Mortein in certain markets, to Lavender Bidco B.V. for £2.172 billion. The proceeds were returned to shareholders through a special dividend of approximately £1.6 billion paid in February 2026. The divestment narrowed Reckitt's portfolio to focus on its highest-growth health and hygiene Powerbrands.

For FY2025, Reckitt reported net revenue of £14.2 billion, with Core Reckitt like-for-like growth of 5.2%. Emerging Markets grew 14.6%, driven by strength in China and India. Europe declined 1.4%, and North America grew 0.2%. Adjusted operating profit was £3.5 billion, up 2.0%, with adjusted operating margin of 24.9%. The company returned £2.3 billion to shareholders through buybacks and dividends.

Reckitt has committed to achieving net zero across its value chain by 2050, with an interim target of carbon neutrality in its own operations by 2040. The company has set science-based targets verified by the Science Based Targets initiative (SBTi). In FY2025, 37.9% of net revenue came from products the company classifies as "more sustainable."

The company is a member of the Roundtable on Sustainable Palm Oil (RSPO). Reckitt has committed to sourcing 100% RSPO-certified palm oil. Its sustainable packaging strategy targets 100% recyclable or reusable packaging by 2030.

Reckitt is not a Certified B Corporation. None of its major subsidiaries hold B Corp certification. The company publishes an annual sustainability report that details its environmental and social performance.

On cruelty-free status, Reckitt's portfolio is mixed. Durex products are not tested on animals. However, some of Reckitt's health brands may be subject to animal testing requirements in certain regulatory jurisdictions where over-the-counter medicines require safety testing. The company does not hold Leaping Bunny or PETA cruelty-free certification at the corporate level.

Reckitt has faced scrutiny over its marketing of infant formula in developing markets. This is a legacy issue that predates Reckitt's ownership of Mead Johnson but carries forward under the Enfamil brand. The World Health Organization's International Code of Marketing of Breast-milk Substitutes restricts marketing of infant formula, and compliance with this code has been a recurring area of regulatory attention for all infant formula manufacturers.

Reckitt has faced several notable regulatory and legal matters. The most significant is the ongoing scrutiny of infant formula marketing practices. In 2022, Reckitt's Mead Johnson division faced investigations in the United States related to infant formula marketing and supply practices during the formula shortage. The US House Oversight Committee launched an investigation into infant formula manufacturers, including Reckitt, examining whether companies engaged in price gouging or misleading marketing during the shortage. The investigation concluded without formal sanctions against Reckitt.

In 2019, Reckitt took a £5.2 billion impairment charge on the Mead Johnson nutrition business, reflecting lower-than-expected growth and challenging market conditions. The impairment was one of the largest in UK corporate history and raised questions about the strategic rationale of the acquisition.

Reckitt has faced product recalls. In 2023, the company recalled certain batches of infant formula in the United Kingdom due to potential bacterial contamination. No serious illnesses were reported, and the recall was completed successfully.

The company has also faced regulatory scrutiny over advertising claims. In 2020, the UK Advertising Standards Authority ruled against certain Dettol advertising claims related to COVID-19 protection, requiring Reckitt to modify its marketing materials. The company complied with the ruling.

In 2024, Reckitt agreed to pay $50 million to settle a class action lawsuit in the United States related to allegations that Mead Johnson had violated antitrust laws by conspiring to restrict infant formula distribution. Reckitt denied the allegations but settled to avoid prolonged litigation.